Chaim Hurvitz

Chief Executive Officer at CH Health

Chaim Hurvitz

Chaim Hurvitz

Chief Executive Officer at CH Health

Overview
Career Highlights

CHealth
CH Health
Teva Pharmaceutical Industries Ltd.

RelSci Relationships

348

Number of Boards

14

Birthday

07/1960

Age

60

Relationships
RelSci Relationships are individuals Chaim Hurvitz likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder, Chief Executive Officer at Galmed Pharmaceuticals Ltd.

Relationship likelihood: Strong

President & Chief Executive Officer at Tushia Consulting Engineers Ltd.

Relationship likelihood: Strong

Former Chief Medical Officer at Galmed Pharmaceuticals Ltd.

Relationship likelihood: Strong

Co-Founder & Senior Managing Director at VV Manager LLC

Relationship likelihood: Strong

Crossbencher at United Kingdom House of Lords

Relationship likelihood: Strong

Founder at Leader Holdings & Investments Ltd.

Relationship likelihood: Strong

Former Chairman & Chief Executive Officer at ViewBix, Inc.

Relationship likelihood: Strong

Venture Partner at MediTech Partners, Inc.

Relationship likelihood: Strong

Chief Executive Officer & Director at Celixir Plc

Relationship likelihood: Strong

Co-Founder & Chief Executive Officer at Pontifax Management Co. Ltd.

Relationship likelihood: Strong

Paths to Chaim Hurvitz
Potential Connections via
Relationship Science
You
Chaim Hurvitz
Chief Executive Officer at CH Health
Education
BA Political Science & Economics
Class of 1985

Tel Aviv University (TAU) (Hebrew: ?????????? ???????? Universitat Tel Aviv) is a public university located in Ramat Aviv, Tel Aviv, Israel. With nearly 30,000 students, TAU is Israel's largest university. Located in Israel's cultural, financial and industrial core, Tel Aviv University is a major center of teaching and research, comprising 9 faculties, 27 schools, 98 departments and 128 research institutes and centers. Its origins go back to 1956, when three research institutes – the Tel Aviv School of Law and Economics, the Institute of Natural Sciences, and the Institute of Jewish Studies – joined together to form the University of Tel Aviv. Initially operated by the Tel Aviv municipality, the university was granted autonomy in 1963. The university also maintains academic supervision over the Center for Technological Design in Holon, the New Academic College of Tel Aviv-Yaffo, and the Afeka College of Engineering in Tel Aviv. The Wise Observatory is located in Mitzpe Ramon.

Memberships
Member
Current

Israel Diamond Manufacturers Association Ltd. engages in the advancement of the diamonds industry and the unification of diamonds producers. The company was founded in 1940 and is headquartered in Ramat Gan, Israel.

Career History
President & Chief Executive Officer
1992 - Prior

Teva is a global generic pharmaceuticals leader and one of the top 15 pharmaceutical companies in the world. Headquartered in Israel, Teva operates in 60 countries and has 46,000 employees worldwide. Established in 1901, Teva takes great pride in its long tradition of leadership and dedication to excellence

Chief Executive Officer
2011 - Current

Chealth is an application that connects patients and healthcare providers to form a personalized care plan.

Chief Executive Officer
2011 - Current
Boards & Committees
Chairman
2019 - Current

Univo Pharmaceuticals Ltd. engages in the development, manufacture, and supply of cannabis products. Its products include dried flowers and extracts. The company was founded by Alexander Kozak, Golan Bitton, Nir Ben Zvi, and Max Herzberg on April 4, 1993 and is headquartered in Tel Aviv, Israel.

Member, Board of Directors
2016 - Current

PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The company was founded by Noam Emanuel in 2008 and is headquartered in Petach Tikva, Israel.

Director
Current

Celixir Plc discovers and develops regenerative medicines to treat life threatening and life altering diseases. It offers heartcel-immunomodulatory progenitor imp cells, tendoncel-platelet lysate based therapy, myocardion-progenitor cells of mesodermal lineage. The company was founded by Martin Evans and Ajan Reginald in 2009 and is headquartered in Stratford-upon-Avon, the United Kingdom.

Investments
Details Hidden

PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The company was founded by Noam Emanuel in 2008 and is headquartered in Petach Tikva, Israel.

Details Hidden

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. It has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. The firm's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's approved product, Jelmyto (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Chaim Hurvitz. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Chaim Hurvitz's profile does not indicate a business or promotional relationship of any kind between RelSci and Chaim Hurvitz.